Randomized clinical trials (RCTs) have long been recognized as the gold standard for testing the safety and efficacy of pharmaceutical interventions. Despite their rigorous methodology, RCTs are not without limitations – logistical demands, recruitment hurdles, elevated costs, selection bias, inability to detect rare and long-term adverse effects, and limited generalizability Read more…
Prelude to Power: OpenAI’s ChatGPT takes the lead In the waning months of 2022, OpenAI unveiled ChatGPT, marking a pivotal moment in the AI landscape. It garnered a staggering 100 million active users within two months, establishing it as the fastest-growing consumer application in history. OpenAI’s momentum continued with the Read more…
Analyzing real-world data (RWD)1 to generate real-world evidence (RWE)2 is an emerging trend in the healthcare community. RWE is routinely used to evaluate a treatment’s real-world effectiveness, safety, and economic value, but it has also been increasingly leveraged in clinical trials. To promote the progression this field, FDA has published Read more…
Large Language Models (LLMs), including ChatGPT, have gained significant traction since late 2022, sparking debates about whether they’re mere hype or a genuine revolution. However, their undeniable utility spans personal and business activities, including but not limited to proofreading and editing, language translation, coding and debugging, and content creation. At Read more…
Congratulations! The decision to embark on the journey of founding a biopharmaceutical company is a courageous step indeed. Remember, as Tony Wheeler put it, “All you’ve got to do is decide to go and the hardest part is over.” Yet this venture is less of a sprint and more of Read more…
“I got diagnosed in my early 20s” “I wanted to so badly say, ‘You guys have no idea. I’m in chemotherapy. You’re a–holes.’ I locked myself away until I was confident and comfortable again,” (despite of sparked rumors of addiction.) “had to take a break from my career last year to deal with Read more…
Humira, a top-selling drug with $200 billion in revenue over two decades, recently lost its patent monopoly. This paved the way for biosimilars like Amjevita to enter the market and offer more affordable treatment options. However, when Amgen launched Amjevita in the US, it had two list prices, $40,500 (55% Read more…
Artificial intelligence (AI), machine learning (ML), deep learning (DL), and natural language processing (NLP) are hard-to-avoid buzzwords at professional conferences, scientific journals, technological news, social media, and, of course, any vendor’s marketing pitch. Many enthusiasts have even made the splash in media that AI is going to revolutionize everything and Read more…